INTRODUCTION
Renal impairment (RI) is one of the most common complications of multiple myeloma (MM). The incidence of RI at diagnosis ranges from 20% to 50%, according to how RI is defined, that is, either as serum creatinine (sCr) above the upper normal limit or . 2 mg/dL or as estimated glomerular filtration rate (eGFR) , 60 mL/min/1.73 m 2 . [1] [2] [3] In the era of conventional chemotherapy (CC), RI was associated with a poor median survival time of approximately 2 years. 4 The use of novel antimyeloma agents resulted in a substantial increase in the survival of patients with MM with RI, although, severe RI is associated with as increased risk of early death. [5] [6] [7] During the last years, several studies reported data on the management of patients with MM with RI. The International Myeloma Working Group (IMWG) reviewed the available evidence and here provides recommendations for the diagnosis and management of myeloma-related RI. 9, 10, 14 Monoclonal immunoglobulin deposition disease (MIDD), amyloidosis, and rarely, kidney infiltration by myeloma cells or acquired adult Fanconi syndrome represent other renal pathologies in patients with MM. [15] [16] [17] In a review of 190 renal biopsies of patients with MM, MIDD and amyloidosis accounted for 22% and 21% of the total pathology, respectively. 15 The terminology of monoclonal gammopathy of renal significance has recently been introduced to describe B-cell monoclonal disorders that do not meet the criteria for the diagnosis of lymphoma or myeloma but produce monoclonal proteins that cause permanent renal injury. These entities are described in Table 2 , and treatment options are suggested. 18, 19 
DIAGNOSIS OF RI IN PATIENTS WITH MM
The definition of RI, according to the novel IMWG criteria for symptomatic MM, is based on either elevated sCr (. 2 mg/dL) or reduced creatinine clearance (CrCl; , 40 mL/min), which have to be the result of myeloma. 20 For evaluation of CrCl, eGFR as assessed by either the Modification of Diet in Renal Disease (MDRD) formula or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation seems to give accurate results that are close to those obtained with the inulin-based GFR estimation in cases of stable sCr. 21, 22 In such patients, classification of RI can be performed by using the five stages of the CKD classification (Appendix Table A2 , online only). 23 CKD-EPI seems to more accurately reflect GFR than does MDRD, mostly in higher levels of GFR. 24, 25 The two equations were evaluated in 1,937 newly diagnosed patients with MM: 9.7% of patients were allocated in different CKD stages by the two methods, mainly because CKD-EPI resulted in lower eGFR. 26 The CKD-EPI group has also suggested that an equation on the basis of both sCr and cystatin-C (CysC), which also reflects tumor burden, is more accurate than other eGFR formulae 21, 27, 28 . However, CysC is not available in all centers; thus, larger studies with health economics data are needed before recommending the wider use of this method for eGFR. b 2 -Microglobulin is another marker that reflects both renal function and tumor burden in patients with MM and is thus also included in the new revised International Staging System. 29 eGFR, however, should be used only in patients with stable renal function. Thus, in cases of acute RI, RIFLE (Risk, Injury, Failure, Loss and End-Stage Kidney Disease) criteria and AKIN (Acute Kidney Injury Network) classification can be used (Table 1) . 30 These criteria are more sensitive for the determination and evaluation of AKI but only limited data exist in the literature for the use of these criteria in MM. In 249 patients with hematologic malignancies who underwent allogeneic or autologous stem cell transplantation (ASCT), RIFLE showed greater sensitivity than did AKIN to identify patients with AKI posttransplant. 31 In another small study of 78 patients with myeloma with AKI, the severity of RI as staged by RIFLE was associated with longterm outcomes. 32 The use of RIFLE and AKIN is encouraged in myeloma studies to define their role in the management of myelomarelated RI. Another important issue is the cause of RI in MM. In . 15% of patients with myeloma with RI, renal biopsy indicated that the cause of RI had no association with the monoclonal gammopathy; RI was a result of arterionephrosclerosis (6%), diabetic glomerulosclerosis (5%), postinfectious glomerulonephritis (2%), or even smokingrelated glomerulopathy (0.5%). 15 Furthermore, the presence of MIDD or amyloidosis must be excluded. As an aid to diagnostic workup, 24-hour urine protein electrophoresis may reveal patterns of protein excretion that may provide clues to the etiology of RI. Predominantly selective proteinuria, consisting of light chains, with limited albumin excretion is most likely a result of CN, whereas larger amounts of albumin or nonselective patterns of proteinuria suggest an alternative pathology. 33 Serum free light chain (sFLC) . 500 mg/L to 1,500 mg/L may be more suggestive of CN.
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Thus, all patients with symptomatic myeloma should have in their diagnostic work-up sCr, electrolytes measurements, and eGFR but also sFLC measurement and electrophoresis of a sample from a 24-hour urine collection. If proteinuria consists predominantly of light chains, a renal biopsy may not be necessary, and the cause of RI may be attributed to myeloma CN. On the contrary, amyloidosis, MIDD, or another underlying condition should be excluded and a renal biopsy could be considered in patients with nonselective proteinuria or albuminuria (Fig 1) . [33] [34] [35] In cases in which amyloidosis is suspected, a subcutaneous fat aspirate may reveal the diagnosis in approximately 70% of patients 35 ; if the fat biopsy is negative, a renal biopsy is required.
Recommendations
CKD-EPI, preferably, or MDRD should be used for the evaluation of renal function in patients with MM with stabilized sCr (grade A). The five stages of CKD should be used to classify these patients (grade A). For patients with acute renal injury, RIFLE and AKIN are more appropriate (grade C); however, these criteria need to be evaluated prospectively in patients with MM. Other formulae, such as the CKD-EPI-sCr-CysC equation, can be used in clinical trials to assess its value in the MM setting. All patients with myeloma at diagnosis and at disease assessment should have sCr and electrolytes measurements as well as urine electrophoresis of a sample from a 24-hour urine collection (grade A). sFLC should be also measured if available (grade A). If nonselective proteinuria or significant albuminuria is detected, a renal biopsy should be performed for the establishment of the cause of the RI (grade B).
CRITERIA FOR THE DEFINITION OF RENAL RESPONSE TO TREATMENT
The definition of reversibility of renal dysfunction is an important issue, and it affects the choice of therapy and the evaluation of patient outcomes. In the case of patients on dialysis, independence from dialysis is a strong indication of improvement. For all other patients, the IMWG had suggested criteria for the definition of renal response to therapy (Table 3) . 36 These criteria have been widely accepted and have been used worldwide for the evaluation of renal response in several studies. [37] [38] [39] [40] [41] Simplified criteria of renal response have also been proposed but must be tested in larger studies before their recommendation (Fig 2) . 42 
Recommendations
IMWG criteria for the definition of renal response should be used in both clinical trials and every day clinical practice (grade B). MDRD or CKD-EPI equations can both be used for the eGFR used in these criteria (grade C).
MANAGEMENT OF PATIENTS WITH MM WITH RI
Acute RI is a myeloma emergency. Diagnosis should be established as fast as possible, and antimyeloma therapy should be started immediately after confirmation of diagnosis to rapidly restore renal function. For patients who require dialysis, the goal of therapy should be independence from dialysis. 
Supportive Care
For all patients in whom myeloma-induced RI is suspected, adequate supportive care is mandatory. This includes adequate hydration with fluids ($ 3 L/d, approximately 2 L/m 2 /d), which is particularly important in patients with fluid depletion resulting from concomitant hypercalcemia. 43, 44 Careful monitoring of fluid balance is recommended for all patients and mainly for those with congestive heart failure. A fluid challenge should be attempted in patients who present with anuria in an attempt to reverse it. Patients with established anuria need fluid monitoring during dialysis.
Urine alkalization is used in several centers; however, data from randomized clinical trials have not proven its value in the reversibility of RI. 44 Management of factors that contribute to RI is crucial; rapid reversal of hypercalcemia may result in improvement of RI in several cases. Bisphosphonates (BPs) or denosumab are licensed for the management of hypercalcemia of malignancy; however, according to current guidelines, BPs (both pamidronate and zoledronic acid) are not indicated for patients with CrCl , 30 mL/min. 45 Denosumab was safe for treatment of patients with solid tumors and RI; caution and close monitoring is needed to guard against the development of hypocalcemia. 46 High-dose steroids and calcitonin can be used safely for treatment of hypercalcemia and RI.
Furosemide is not recommended as it may enhance cast formation in the renal tubules. 47 BPs for myeloma-related bone disease should be delayed until GFR has improved.
Recommendations
High fluid intake ($ 3 L/d or approximately 2 L/m 2 /d) can be started with antimyeloma therapy (grade B). Urine alkalization seems not to offer advantage in the reversal of RI in myeloma (grade B). Bisphosphonates can reduce calcium levels in the case of hypercalcemia but neither pamidronate nor zoledronic acid should be used in patients with severe RI (CrCl , 30 mL/min; grade A). Denosumab may be useful in patients with hypercalcemia and RI but calcium levels must be closely monitored (grade C). Avoidance of nephrotoxic agents, such as aminoglycoside antibiotics, furosemide, and contrast agents, is highly recommended for patients with MM with RI (grade A).
Mechanical Approaches
Plasma exchange. Two studies in the CC era suggested that plasma exchange was able to reverse RI in patients with myeloma, 48, 49 whereas a prospective study with a low number of patients (n 5 21) reported only a trend in favor of plasma exchange, 50 and a larger randomized trial (n 5 104) failed to show a clear advantage of plasma exchange regarding dialysis independence. 51 However, the latter study was limited by the lack of histologic confirmation of CN. The combination of bortezomib-based chemotherapy and plasma exchange offered a dramatic reduction of free light chain (FLC; 75% to 96%) in a small Mayo Clinic study (n 5 14). 52 A recent meta-analysis that included three randomized studies with patients who received chemotherapy only (n 5 63) or both chemotherapy and plasmapheresis (n 5 84) showed that the 6-month dialysis dependency ratio was significantly lower in patients treated with both chemotherapy and plasmapheresis than in chemotherapy alone (15.6% v 37.2%; risk ratio, 2.02; P 5 .04). However, there was no difference in overall survival (OS) between the two groups. 53 High-cutoff hemodialysis. The use of the high-cutoff hemodialysis (HCO-HD) membranes, which allow the removal of FLCs through their larger pores (molecules # 60 kD to 65 kD can be removed), has produced encouraging results in the reduction of FLCs and the reversal of RI. In a study of 67 patients with myeloma with dialysis-dependent RI, the use of HCO-HD in combination with antimyeloma therapy produced a sustained reduction of FLCs in 67% of patients by day 12 and caused dialysis independency in 63%. The most important factors that predicted independence from dialysis were the degree of FLC reduction on days 12 (P 5 .002) and 21 (P 5 .005) and the time to initiation of HCO-HD (P 5 .006). 54 Similar results were confirmed in smaller studies. 55, 56 Currently, two prospective randomized studies, the European multicenter, randomized controlled EuLITE study (European Trial of Free Light Chain Removal by Extended Hemodialysis in Cast Nephropathy; NCT00700531) and the French MYRE study (Studies in Patients With MM and Renal Failure Due To Myeloma Cast Nephropathy; NCT01208818) are evaluating the role of HCO-HD in the recovery of RI in patients with MM who receive bortezomib-based antimyeloma therapy.
Long-term dialysis. End-stage RI requires long-term dialysis. Patients on dialysis have an increased risk of death of approximately 15% to 30% within the first months of diagnosis. 5, 57 The Simplified criteria of renal response have been proposed: Patients who presented with stage 5 renal impairment (RI) should double their estimate glomerular filtration rate (eGFR) and improve to at least stage 4 to be defined as responders, whereas patients with stage 4 RI must increase their eGFR by at least 50% and improve to at least stage 3 (GFR $ 60 mL/min) to be considered as having renal response. These criteria were evaluated in 105 unselected patients with newly diagnosed multiple myeloma with severe RI who received treatment on the basis of high-dose dexamethasone (Dexa; 19%), bortezomib (38%) or immunomodulatory drugs (IMiDs; 43%). There were no differences in renal responses with the use of the standard International Myeloma Working Group (IMWG) criteria versus the simplified criteria. response rate to antimyeloma therapy is between 40% and 60%, whereas the median survival time of patients on long-term dialysis is approximately 2 years, with 30% surviving for . 3 years.
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Recommendations
Current data supports the use of HCO-HD in combination with antimyeloma therapy for patients with myeloma with acute RI as a result of CN (grade B). In the case that HCO-HD is unavailable, plasma exchange may be of benefit in select patients with proven acute RI or that which is strongly suspected to be related to light chain CN (grade C).
Antimyeloma Therapy
Systemic antimyeloma therapy must start immediately to reduce the load of toxic FLCs and thus improve renal function.
CC and high-dose corticosteroids. CC has been used in the past mainly for the management of patients with myeloma with RI. In a large study (the Medical Research Council IV trial; n 5 554), approximately one half of patients with acute RI died within 3 months of CC initiation, whereas 44% of patients (39 of 80) who were alive for . 100 days experienced a complete reversal of RI, which was defined as sCr , 1.5 mg/dL.
60 CC with standard-dose corticosteroids produces 25% to 50% of renal recovery. 61 In the VISTA trial, 34% of patients with RI (CrCl , 50 mL/min, mostly moderate RI) who received MP managed to achieve a renal complete response (CR) at a median of 2.4 months.
62 High-dose corticosteroids (equivalent to dexamethasone $ 160 mg over 4 days; in the majority of studies, dexamethasone 40 mg, 4 days on and 4 days off, for 3 pulses in a 28-day cycle) are effective in improving RI, with renal responses # 65%, compared with conventional doses of corticosteroids. [63] [64] [65] [66] The administration of high-dose dexamethasone-$ 160mg in the first month of therapy-was associated with a more rapid renal response, even in patients treated with immunomodulatory drugs (IMiDs) or bortezomib, in a retrospective analysis of 133 patients with newly diagnosed myeloma (NDMM) with RI (1.6 v 46 months for doses of , 160 mg; P 5 .008).
38 Table 4 includes possible dose modifications of most common antimyeloma drugs according to renal function.
IMiD-based regimens. Thalidomide is not excreted by the kidneys and thus does not need dose modification. The renal recovery expected with thalidomide-based regimens (usually in combination with high-dose corticosteroids) ranges from 55% to 75% in patients wth NDMM and is approximately 60% in patients with relapsed/refractory (RR) disease (Table 5) . 38, [67] [68] [69] 78 Special concern is needed for patients on dialysis in whom an unexplained hyperkalemia has been observed. 67, 79 Lenalidomide is excreted through the kidneys and thus requires dose adjustments according to the degree of RI. 80 In the major phase III trials that evaluated the combination of lenalidomide and high-dose dexamethasone in RR MM, 82 patients had moderate RI (CrCl , 60 mL/min) and 16 had severe RI (CrCl , 30 mL/min). Lenalidomide 25 mg was administered without dose adjustment for RI. There were no differences in response rates, response quality, time to progression, or progressionfree survival (PFS) among patients with different stages of RI, whereas there was a trend toward decreased OS in patients with moderate or severe RI. Importantly, 72% of patients with RI experienced improved renal function by at least one level (from severe to moderate or from moderate to mild or no RI). 71 In a recent phase II study, dose-adjusted lenalidomide with high-dose dexamethasone was administered to 35 patients with acute RI. Myeloma responses were observed in 69% of patients (CR, 20%), whereas renal response was observed in 45% of patients (CR, 14%; partial response, 11%; minor response, 20%). Five of 13 patients requiring dialysis at baseline became dialysis independent. The median times to best myeloma response and best renal response were 92 days and 157 days, respectively. 41 Increased toxicity, mainly neutropenia, thrombocytopenia, and infections, were observed in patients with RI in both studies. 41, 71 Similar results for efficacy and toxicity have been observed in several studies with lenalidomide in patients with MM with RI (Table 5) . 70, [72] [73] [74] [75] Pomalidomide, the third-generation IMiD, is metabolized before excretion and only 2% of the parent drug is thus excreted in the urine. Results from phase III studies suggest that pomalidomide requires no dose adjustment in patients with CrCl $ 45 mL/min. 81 In a subanalysis of the phase IIIb STRATUS trial, pomalidomide at a dose of 4 mg produced similar objective response rate (ORR) and PFS in patients with and without moderate RI (CrCl , 60 mL/min and CrCl $ 60 mL/min, respectively), although there was a trend for prolonged PFS in the group with CrCl $ 60 mL/min (Table 5) . 77 Pomalidomide is being further studied in patients with CrCl , 45 mL/min.
Proteasome inhibitor-based regimens. Combinations of bortezomib, which has a half-life independent of renal clearance, with dexamethasone (VD) or with melphalan and prednisone for elderly patients have been considered to date the standard of care for patients with MM with RI. 36 This has been confirmed by several studies in which the rapid reduction of tumor load by bortezomib along with its nonrenal metabolism had led to high ORR, renal responses, and dialysis independence rates (Table 6) . 38, 39, 62, [82] [83] [84] [85] [86] [87] [88] In a retrospective large analysis that included 133 patients with NDMM with RI, a significant improvement of renal function ($ renal partial response) was observed in 77% of patients treated with bortezomibbased regimens versus 55% and 43% for patients treated with thalidomide-or lenalidomide-based regimens, respectively. Bortezomib was used more often in patients with severe RI or in patients requiring dialysis; however, higher doses of dexamethasone were used in combination with bortezomib. 38 The addition of a third drug to VD seems to improve renal outcomes. 89 In the prospective HOVON-65/GMMG-HD4 study, patients were randomly assigned to receive three cycles of VAD (vincristine, doxorubicin, dexamethasone) or PAD (bortezomib, doxorubicin, dexamethasone) followed by ASCTand maintenance with thalidomide (VAD arm) or bortezomib (PAD arm). Baseline sCr was $ 2 mg/dL in 81 patients who achieved a renal response rate of 63% in the VAD arm and 81% in the PAD arm. OS at 3 years for these patients was 34% in the VAD arm and 74% in the PAD arm (P , .001). 88 Response at 8 years was 12% and 47%, respectively. 90 Two randomized studies have shown that the subcutaneous use of bortezomib produced results similar to intravenous administration in patients with RI.
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Carfilzomib is a second-generation proteasome inhibitor that has been licensed for the management of RR MM. In a recent study, there were no differences in carfilzomib clearance among patients with normal renal function and with various degrees of RI. Similarly, there was no difference in ORR and toxicity among the different RI groups. 93 In a recent, phase III randomized trial, treatment with carfilzomib plus dexamethasone (n 5 464) was compared with treatment with bortezomib plus dexamethasone (n 5 465) in 929 patients with RRMM who had received one to three prior lines of therapy. Inclusion criteria included CrCl $ 15 mL/min. Carfilzomib was found to be superior to bortezomib for median PFS (18.7 v 9.4 months), which supported previous observations that carfilzomib can be also administered to patients with RI. Acute renal failure (grade 3 and 4) was noted in 7% of patients in the carfilzomib arm versus 4% in the bortezomib arm. 94 Ixazomib is the first oral proteasome inhibitor recently approved by the US Food and Drug Administration in combination with lenalidomide and dexamethasone for patients with RR MM, who have received one to three prior lines of therapy. The phase III randomized study that led to the approval of the combination included patients with CrCl $ 30 mL/min. 95 On the basis of the results of the study, this combination can be safely administered to patients with myeloma with CrCl $ 30 mL/min.
ASCT. High-dose therapy (HDT) with ASCT remains the treatment of choice for eligible patients with NDMM, and is feasible even in patients who require dialysis. 96 RI does not to affect the CD34 1 yield or their engraftment. 97 Melphalan dose needs to be adjusted (100 to 140 mg/m 2 ), but seems to be as effective as the 200 mg/m2 dose 98 ; however, the procedure is associated with an increased risk of transplant-related mortality for patients with RI (. 4%) compared with patients without RI at the time of transplantation (, 1%). [96] [97] [98] Retrospective analyses have reported a $ 25% improvement in RI in one third of patients, a 15% to 20% probability of dialysis independence, and a 5-year OS of nearly 35%. 98, 99 Novel agents may further improve these results. In a recent study, 27 patients on dialysis received induction therapy with either bortezomib or CC (mainly VAD) followed by HDTwith ASCT. ORR was higher after bortezomib-based induction (83% v 36%; P 5 .02) and at day . 100 post-ASCT (100% v 58%; P 5 .01). Bortezomib also prolonged PFS and produced a trend toward a decreased time on hemodialysis (6 v 17 months in patients who received CC). 100 Kidney transplantation in patients with myeloma with end-stage renal disease. There are some case reports and small case studies in which kidney transplantation has been offered to patients with MM who have sustained CR for several years 101 ; however, the data are limited in the literature.
Recommendations
Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). Bortezomib should be started at the standard dosage of 1.3 mg/m 2 on days 1, 4, 8, and 11 of a 3-week cycle (grade A), and high-dose dexamethasone should be administered for at least the first month of therapy (grade B). Subcutaneous administration of bortezomib has efficacy similar to intravenous administration (grade A). The recommended dosage of high-dose dexamethasone is 40 mg/d (20 mg/d for patients age $ 75 years), 4 days on and 4 days off, for the first cycle of therapy, then by treatment protocol. The addition of a third drug to VD seems to be beneficial. In patients eligible for ASCT, bortezomib could be administered in combination with CC (doxorubicin or cyclophosphamide) or thalidomide and dexamethasone (grade A). In patients who are ineligible for ASCT, bortezomib with melphalan and prednisone can also be administered (grade B), but no data exist for this regimen in patients on dialysis. Thalidomide is effective in patients with myeloma with RI (grade B) and should be administered without dose modification (grade A). Lenalidomide is also effective and safe, mainly in patients with mild to moderate RI (grade B), and should be administered with dose adjustments according to patient CrCl level (grade A). Lenalidomide can be also administered to patients with severe RI or to Abbreviations: Bor, bortezomib; BPV, bendamustine, prednisone, and bortezomib; CC, conventional chemotherapy; CR, complete response; CrCl, creatinine clearance; Dexa, dexamethasone; eGFR, estimate glomerular filtration rate; GFR, glomerular filtration rate; MP, melphalan and prednisone; MR, minor response; nCR, near complete response; NR, not reported; ORR, objective response rate; OS, overall survival; PAD, bortezomib, doxorubicin, and dexamethasone; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; PR, partial response; sCr, serum creatinine; TTP, time to progression; VAD, vintristine, doxorubicin, dexamethasone; VCD, bortezomib, cyclophosphamide, and dexamethasone; VD, bortezomib and dexamethasone; VGPR, very good partial response; VMP, bortezomib, melphalan, prednisone; VTD, bortezomib, thalidomide, dexamethasone.
patients on dialysis but patients should be closely monitored for hematologic toxicity (grade B). HDT with ASCT is feasible in patients with myeloma with RI; the dose of melphalan should be restricted to 100 to 140 mg/m 2 (grade C). Pomalidomide should be administered in a dosage of 4 mg/d in patients with CrCl $ 45 mL/ min (grade A); additional studies will reveal if the dose should be reduced for more severe RI. Carfilzomib is another option for patients with RR MM and RI and it needs no dose modification and produces similar results in patients with and without RI (grade A for patients with CrCl $ 15 mL/min; grade B for patients with CrCl , 15 mL/min). More data are needed regarding its renal safety. Ixazomib can be safely administered in combination with lenalidomide and dexamethasone in patients with RR MM and CrCl $ 30 mL/min (grade A). 
